Schisanhenol is a novel and potent bioactive compound.

Lonafarnib (formerly SCH66336; SCH-66336; Sarasar; Zokinvy), a tricyclic derivative of carboxamide, is a novel, orally bioavailable and highly potent FPTase (farnesyl protein transferase) inhibitor with potential anticancer activity.

Tolcapone (Ro 40-7592; SOM-0226; Ro-407592; Tasmar), an approved anti-Parkinson’s disease (PD) agent, is a reversible and orally bioavailable inhibitor of catechol-O-methyl transferase (COMT) with potential anti-PD effects.

LB42708 (LB-42708; LB 42708) is a novel, potent, orally bioactive, and nonpeptidic farnesyltransferase (FTase) inhibitor with potential anti-inflammatory activity.

GGTI 298 TFA (GGTI-298), the trifluoroacetic acid salt of GGTI 298, is a novel and potent geranylgeranyltransferase I (GGTase-I) inhibitor with ability to arrest human tumor cells in the G1 phase of the cell cycle and induce apoptosis.

Tipifarnib (R-115777; LX-81; R115777; NSC-702818; D03720; Zarnestra), non-peptidomimetic quinolinone analog, is a potent and selective farnesyltransferase (FTase) inhibitor with potential antineoplastic activity.

PF-04620110 (PF04620110; PF 04620110) is a novel, potent, orally bioactive, and selective diglyceride acyltransferase-1 (DGAT1) inhibitor with the potential to treat type 2 diabetes mellitus.

FTI 277 HCl (FTI-277; FTI277), the HCl salt of FTI 277, is a peptide mimetic of the COOH-terminal Cys-Val-Ile-Met of K-Ras4B which is a novel, potent and selective farnesyltransferase (FTase) inhibitor with antiviral activity.

Daporinad (APO866; FK-866; APO-866; K 22.175) is a novel and potent inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase) with potential antitumor and antiangiogenic activity.

A922500 (A-922500; A 922500) is a selective and orally bioactive inhibitor for human/mouse acyl CoA/diacylglycerol acyltransferase(DGAT-1) with anti-hyperlipidemic effects.